Objective-Chronic administration of selective cyclooxygenase-2 (COX-2) inhibitors leads to an increased risk of adverse cardiovascular events, including myocardial infarction and stroke. Vascular smooth muscle cell (VSMC) calcification, a common complication of chronic kidney disease, is directly related to cardiovascular morbidity and mortality. Here, we tested whether specific COX-2 inhibition affects vascular calcification during chronic renal failure. Approach and Results-The COX-2-specific inhibitors NS398 and SC236 significantly increased high-phosphate (Pi)-induced VSMC calcification. Similarly, COX-2 −/− VSMCs, COX-2 −/− aortas rings treated with high Pi and adenine dietinduced COX-2 −/− chronic renal failure mice displayed enhanced calcium deposition. Metabolomic analysis revealed the differential suppression of PGE 2 production by COX-1-and COX-2-specific inhibitors in high-Pi-stimulated VSMCs, indicating the involvement of PGE 2 during COX-2 inhibition-aggravated vascular calcification. Indeed, exogenous PGE 2 reduced alkaline phosphatase activity, osteogenic transdifferentiation, apoptosis, and calcification of VSMCs. In accordance, downregulation of microsomal prostaglandin E synthase (mPGES)-1 in VSMCs, mPGES-1 −/− aorta with high-Pi stimulation and mPGES-1 −/− chronic renal failure mice resulted in enhanced vascular mineralization. Further applications of RNAi and specific antagonists for PGE 2 receptors indicated EP4 may mediate PGE 2 -inhibited vascular calcification. 
C hronic administration of selective cyclooxygenase-2 (COX-2) inhibitors, particularly rofecoxib, valdecoxib, and parecoxib, alleviates pain and inflammation, but increases the risk of myocardial infarction, stroke, systemic and pulmonary hypertension, congestive heart failure, and sudden cardiac death. [1] [2] [3] It has been proposed that the increased cardiovascular risk is primarily attributable to the suppression of vasodilator and antiaggregator prostaglandin I 2 (PGI 2 ) production. 4 However, the underlying mechanisms are yet to be fully understood.
Microsomal prostaglandin E synthase-1 (mPGES-1), which catalyzes the isomerization of PGH 2 into PGE 2 , has emerged as an alternative drug target to COX-2 because of its reduced susceptibility to hypertensive or thrombogenic stimuli, and augmented PGI 2 production via mPGES-1 inhibition. 5 Indeed, global mPGES-1 null mice exhibit a reduced formation of neointima and abdominal aortic aneurysms. 6 Nevertheless, it remains elusive whether specific mPGES-1 inhibition always limits cardiovascular hazards.
Vascular calcification, the aberrant deposition of calciumphosphate crystals in the vessel wall, contributes directly to cardiovascular morbidity and mortality among aging individuals and patients with chronic renal failure (CRF), atherosclerosis, or diabetes mellitus. 7 Recent data also indicate that vascular calcification is an accurate predictor of cardiovascular events, including myocardial infarction and stroke. The pathogenesis of vascular calcification involves the osteochondrogenic transformation of vascular smooth muscle cells (VSMCs), apoptosis, matrix vesicle release, matrix remodeling, and an imbalance between inducers and inhibitors of vascular calcification. 8 Compelling evidence indicates that vascular calcification is an active and highly regulated process that shares many similarities to bone mineralization 9 ; however, the detailed mechanism of this process requires further exploration. Interestingly, a variety of arachidonic acid metabolites have been reported to be involved in bone mineralization. PGE 2 was identified to have both stimulatory and inhibitory effects on bone formation in cell and organ cultures. 10, 11 In addition, the increased bone mass was observed in adult PGI 2 -deficient mice. 12 The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibited osteoblastogenesis and is potentially involved in osteoporosis. 13 However, there are limited data accounting on the roles of arachidonic acid and its metabolites in vascular calcification.
COX-2 and its products including PGE 2 have been identified as the mediators of renal injury or chronic renal disease via promoting inflammation.
14 Using of the nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) or selective COX-2 inhibitors has also been proposed to be a favorable strategy to reduce proteinuria in addition to renin-angiotensin-aldosterone system blockade for patients with a high risk of proteinuria driven progression to end-stage renal disease. 15 Whether this strategy may bring side effect to cardiovascular system needs to be carefully examined.
Here, we tested whether COX-2-specific inhibitors aggravate vascular calcification. By using a metabolomic approach and CRF mice model, we identified that repression of COX-2-mPGES-1-derived PGE 2 attributable for an enhancement of vascular calcification.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Specific Inhibition of COX-2 Aggravates VSMCs Calcification
We first explored whether COX-2 was involved in VSMC calcification. By adopting a high-Pi (2.6 mmol/L inorganic phosphate)-induced rat VSMC calcification model, we assessed the effect of the COX-2-specific inhibitors NS398 and SC236, 16 the COX-1-specific inhibitor SC560, 17 and the NSAID indomethacin on vascular mineralization. The specific inhibition of COX-2 by NS398 or SC236 (0.1-1.0 μmol/L) enhanced calcium deposition in VSMCs ( Figure 1A and 1B), as demonstrated by calcium deposition and Alizarin red S staining of calcium accumulation. By contrast, the nonselective COX inhibitor indomethacin (1.0 μmol/L) or the specific inhibition of COX-1 by 1.0 μmol/L SC560 showed no effect on VSMC calcification ( Figure 1C and 1D) . A similar effect was observed in human VSMCs ( Figure I in the onlineonly Data Supplement).
To exclude the possible off-target effects of synthetic COX-2-specific inhibitors (NS398 or SC236) involved in VSMC calcification, COX-2 gene was targeted for further study. In accordance, specific COX-2 silencing ( Figure II in the online-only Data Supplement) by siRNA markedly increased calcium deposition in VSMCs with high-Pi stimulation ( Figure 1E ), whereas scrambled siRNA did not exhibit any effect. To further verify these observations, we performed additional ex vivo aortic ring assays with COX-2 −/− mice. Compared with wild-type (WT) mice, the aortic rings of COX-2 −/− mice showed a significant increase of calcium deposition and von Kossa staining with high-Pi stimulation ( Figure 1F and 1G ). In addition, considering the prevalence of vascular medial calcification in patients with CRF, 7 we adopted a modified adenine diet-induced CRF mice model 18, 19 ( Figure 1H ) for exploring the role of COX-2 in vascular calcification in vivo. On the basis of Table I in the online-only Data Supplement, the body weight of WT and COX-2 −/− mice fed with adenine diet was significantly decreased compared with chow diet mice, respectively. The adenine diet mice showed a significant increase in plasma level of blood urea nitrogen, creatinine, as well as phosphorus (Pi) and calcium, indicating the success induction of CRF in both WT and COX-2 −/− mice. There was no significant difference between WT and COX-2 −/− mice in terms of renal dysfunction. Mild vascular calcification was observed in WT CRF mice as evidenced by calcium assay, alkaline phosphatase (ALP) activity measurement and von Kossa staining in the aorta. COX-2 −/− mice exhibited greater vascular calcification in abdominal arteries compared with WT mice during CRF state ( Figure 1I and 1K) . Together, these data suggest that specific COX-2 inhibition may aggravate vascular calcification during CRF.
Metabolomic Profiling of Calcifying VSMCs
To explore the underlying mechanisms of the differential effects of COX-1 and COX-2 inhibitors on VSMC calcification, we next performed a systemic metabolomic analysis by ultra-performance liquid chromatography tandem mass-spectrometry. This led us to determine quantitative levels of 31 species of arachidonic acid metabolite of COX, lipoxygenase, and cytochrome P450-catalyzed pathways in the supernatant of VSMCs. High-Pi stimulation in rat VSMCs primarily stimulated COX-catalyzed pathways but not lipoxygenase-or cytochrome P450-mediated pathways except 14,15-DHET (14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic acid; Table II in the online-only Data Supplement). Among the metabolites of COX-catalyzed pathway, PGE 2 and PGI 2 (6-keto-PGF 1 α) were overtly induced by high Pi, whereas thromboxane B 2 was not altered (Figure 2A ; n=3; P<0.05). Of particular interest, PGE 2 was preferentially suppressed by the COX-2-specific inhibitor NS398, but not the COX-1-specific inhibitor SC560, whereas PGI 2 production was reduced by both NS398 and SC560 (Figure 2A) . To verify the metabolomic data, a quantitative ELISA analysis was performed. Accordingly, the selective inhibition of high-Pi-induced PGE 2 was observed after treatment with the specific COX-2 inhibitor but not the COX-1 inhibitor in VSMCs ( Figure 2B ). Intriguingly, high Pi significantly enhanced PGE 2 production as early as 24 hours on exposure and maintained an elevated level until 72 hours ( Figure 2C ). Moreover, similar data were obtained in human VSMCs ( Figure III in the online-only Data Supplement). In adenine diet-induced CRF mice model, plasma PGE 2 was significantly increased after the administration of adenine diet compared with chow diet in WT mice, whereas no enhanced PGE 2 production was observed in COX-2 −/− mice with greater aortic calcification ( Figure 2D ). Furthermore, PGE 2 production was also measured in aortic media and adventitia isolated from WT mice, respectively. As a result, medial PGE 2 was significantly elevated by feeding adenine diet, but no change was observed in adventitial tissues ( Figure 2E ). Above all, these data indicate that aberrant PGE 2 metabolism may be involved in VSMC calcification aggravated by COX-2 inhibitor.
PGE 2 Inhibits VSMC Calcification
Next, we tested whether PGE 2 affects VSMC mineralization. Increasing amount of PGE 2 (0.1-10 μmol/L) inhibited calcium deposition in rat VSMCs stimulated with 2.6 VSMC calcification results in enhanced ALP activity, osteogenic transdifferentiation, and apoptosis. We next examined which of these steps was involved during PGE 2 A, The concentrations of PGE 2 , TXB 2 , and 6-keto-PGF1α in the supernatant were measured by ultra-performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) after high-Pi stimulation with or without NS398 or SC560 treatment for 3 days in rat vascular smooth muscle cells (VSMCs). Three independent experiments were performed in duplicate. B, Quantitative ELISA analyses of the supernatant concentrations of PGE 2 and 6-keto-PGF1α in VSMCs stimulated with or without high-Pi in the absence or the presence of NS398 or SC560 for 3 days; n=3. C, The supernatant concentration of PGE 2 was measured with ELISA after high-Pi stimulation at12, 24, 48, and 72 hours in rat VSMCs, respectively. Three independent experiments were performed in duplicate. D, The plasma concentration of PGE 2 in wild-type and COX-2 −/− mice fed with adenine or chow diet was measured via ELISA (n=6-8 per group). *P<0.05. E, Quantification of PGE 2 in aortic media and adventitia of mice fed with chow or adenine diet by ELISA (n=6-8 per group). *P<0.05. inhibition. Notably, PGE 2 suppressed the high-Pi-enhanced ALP activity in both the supernatant and the cell lysate of rat and human VSMCs 3 days after stimulation ( Figure 3C ; Figure IVB in the online-only Data Supplement). In addition, PGE 2 treatment markedly circumvented the repression of contractile makers of VSMCs (α-actin, SM-22α, and calponin) and the enhancement of osteochondrogenic markers (BMP-2 [bone morphogenetic protein], Runx2, and Msx2) 3 days after high-Pi stimulation ( Figure 3D ). Furthermore, apoptosis at the late stage of calcification (12 days) was also reduced by PGE 2 as evidenced by alterations in the expression of Bax, Bcl-2, and cleaved caspase-3 ( Figure 3E ). Taken together, these data show that PGE 2 inhibits VSMC calcification in vitro.
COX-2 and mPGES-1-derived PGE 2 Confers an Inhibition of Vascular Calcification
The biosynthesis of PGE 2 requires both COX and prostaglandin E synthase (PGES). There are 3 isoforms of PGES, including mPGES-1, mPGES-2, and cytosolic PGES. A recent study suggests that mPGES-1 is the dominant source of PGE 2 biosynthesis under basal conditions or during inflammatory states in mice. 20 Therefore, we tested whether interference of PGE 2 metabolism via the COX and PGES pathways could affect vascular calcification. Indeed, the mRNA levels of COX-2 and mPGES-1 were markedly induced by high Pi. By contrast, the mRNA levels of COX-1, mPGES-2, and cytosolic PGES were not altered or slightly increased by high Pi in VSMCs ( Figure 4A ). Accordingly, the protein levels of COX-2 and mPGES-1 in VSMCs were significantly increased by high Pi as early as 24 hours post stimulation ( Figure 4B ). Similar changes were observed in human VSMCs ( Figure V in the online-only Data Supplement). Furthermore, we analyzed COX-2 and mPGES-1 expression in 2 independent calcification models, the adenine diet-induced mice CRF model and the rat CRF model induced with 5 of 6 nephrectomy plus calcitriol as we validated previously. 21 In the diet-induced mice model, the COX-2 and mPGES-1 protein expression in calcified vessels were significantly upregulated ( Figure 4C ). Furthermore, histoimmunostaining results showed that COX-2 and mPGES-1 predominantly located in medial SMCs of calcified aorta ( Figure 4D ), but a mild to moderate expression of COX-2 and PGES-1 were also observed in pericytes and macrophages in aortic adventitia ( Figure VI in the online-only Data Supplement). Similarly, the increments of these 2 proteins after calcification were mainly observed in aortic media but not adventitia as evidenced by Western blot analysis of COX-2 and mPGES-1 in medial and adventitial layers, respectively ( Figure 4E ), indicating that COX-2 and mPGES-1 in response to calcification induction were predominantly derived from VSMCs. To further validate the distribution of COX-2 and mPGES-1 expression in another CRF model, the 5 of 6 nephrectomy plus calcitriol model were applied. First, vascular calcification was successfully induced in rats, as evidenced by von Kossa staining and aortic calcium deposition. 21 Indeed, the COX-2 and mPGES-1 protein expression in calcified vessels were significantly upregulated in the rat CRF model ( Figure VIIA in the online-only Data Supplement). Moreover, the elevated COX-2 and mPGES-1 in 5 of 6 nephrectomy-induced CRF rats were observed to mainly locate in aortic smooth muscle cells ( Figure VIIB and VIIC in the online-only Data Supplement).
To further address the role of mPGES-1-derived PGE 2 in VSMC calcification, mPGES-1 was specifically silenced in VSMCs ( Figure VIII in the online-only Data Supplement). As shown in Figure 5A , mPGES-1 silencing greatly enhanced calcium deposition within VSMCs compared with scrambled siRNA-treated cells; exogenous 0.1 μmol/L PGE 2 ameliorated this effect. In line with the effect of PGE 2 , mPGES-1 silencing enhanced high-Pi-induced ALP activation, osteogenic transdifferentiation, and VSMC apoptosis ( Figure 5B-5D ). In addition, we assessed the ex vivo calcification in aortic rings of mPGES-1 −/− mice. Compared with WT mice, aortic rings from mPGES-1 −/− mice showed a significant increase in calcium deposition and von Kossa staining in response to high-Pi stimulation ( Figure 6A and 6B) . To investigate the role of mPGES-1-derived PGE 2 in vascular calcification in vivo, adenine diet-induced CRF model was applied. Referring to Table III in the online-only Data Supplement, plasma blood urea nitrogen, creatinine, and Pi were markedly increased by administration of adenine diet in both mPGES-1 −/− and littermates WT mice, suggesting the diet-induced CRF. As well, PGE 2 was significantly elevated in the plasma of WT CRF mice, but not in mPGES-1 −/− mice ( Figure 6C ). The calcium deposition detected by calcium assay and von Kossa staining as well as ALP activity in aortic tissues, indicating the extent of vascular calcification, were all significantly increased in mPGES-1 −/− CRF mice compared with WT littermates (Figure 6D-6F ). 
PGE 2 Represses Pi-Induced VSMC Calcification
Mainly Through EP4 Receptor PGE 2 exerted its functions via specific receptors including EP1, EP2, EP3, and EP4, which are all expressed in VSMCs. 22 We first detected EP1-4 expressions in VSMCs with or without high-Pi treatment. As a result, EP2 and EP4, not EP1 and EP3, were significantly increased by high Pi at both protein and mRNA levels ( Figure 7A and 7B) . To further elucidate the functional receptor of PGE2, specific EP antagonists were applied. EP4 antagonist was uniquely found to enhance high-Pi-induced calcium deposition in VSMCs ( Figure 7C ). Furthermore, EP2 and EP4 siRNA were applied to knockdown gene expression validated by real-time polymerase chain reaction ( Figure IX in the online-only Data Supplement). Consistently EP4 not EP2 knockdown by siRNA increased high-Pi-induced calcium deposition in VSMCs ( Figure 7D and 7E) . Furthermore, EP4 not EP2 silencing also enhanced high-Pi-elevated osteogenic gene expressions ( Figure X in the online-only Data Supplement).These data indicated EP4 may mediate PGE 2 regulation in high-Pi-induced VSMC calcification.
Taken together, our data suggested that the upregulated expression of inducible COX-2 and mPGES-1 leads to the increased production of PGE 2 , which negatively regulates calcification. Specific COX-2 or mPGES-1 inhibition may lead to aggravated calcification and increased cardiovascular risks during CRF. 
Discussion
The major finding of our study is that the inhibition of PGE 2 biosynthesis by COX-2 or mPGES-1 suppression aggravates vascular calcification during CRF. Second, special caution needs to be taken in the development of selective mPGES-1 inhibitors for clinical applications, especially for susceptible patients having CRF.
Compared with traditional NSAIDs, specific COX-2 inhibitors (Coxibs) are less toxic to the gastrointestinal tract, but exhibit greater toxicity to the cardiovascular system. There are several proposed mechanisms for these effects. First, the selective inhibition of COX-2 disrupts the physiological balance between TXA 2 and PGI 2 , thus increasing atherosclerosis, thrombogenesis, and the risk of cardiovascular complications. 23, 24 Second, COX inhibition can raise arachidonic acid levels, which can inhibit mitochondrial oxidative phosphorylation and increase the generation of reactive oxygen species; overt oxidative stress in the vascular system evokes a variety of cardiovascular diseases. Third, COX inhibition can alter lipoxygenase or cytochrome P450 branches of the arachidonate and linoleate cascades, which can cause unexpected cardiovascular effects. A recent metabolomic profile of murine plasma revealed dramatically higher levels of 20-HETE (hydroxyeicosatetraenoic acid) and enhanced platelet aggregation after chronic administration of rofecoxib, which may contribute to myocardial infarction and stroke. 25 Herein, we propose an additional explanation for adverse cardiovascular effects by showing that reduced PGE 2 production as a result of COX-2 inhibition-aggravated high-Pi-induced VSMC and aortic calcification. The latter has been associated with increased all-cause mortality, cardiovascular mortality, and coronary events. 2, 3 Interestingly, it has been clearly established that the excess mortality associated with rheumatoid arthritis is primarily because of cardiovascular disease, especially coronary heart disease. 26 Patients with rheumatoid arthritis have the earlyonset diffuse calcification including multiple vascular beds compared with age-and sex-matched controls. 27 Considering the broad application of COX-2 selective NSAIDs to relieve pain and inflammation in rheumatoid arthritis, it is conceivable that COX-2 inhibition may be a partial explanation for the greater vascular calcification in those patients. Conversely, previous study showed that 26-week-old apoE −/− mice fed with 15-week Celecoxib, COX-2 inhibitor, displayed no changes in advanced atherosclerotic lesion composition, including calcification. 28 After all, atherosclerotic intima calcification involved complex cellular and molecular mechanism and is somewhat different from media VSMC calcification during CRF, aging or diabetes mellitus. 29 At present, there is no epidemiological study showing the association between long-term application of coxibs and vascular calcification. Additional studies are needed to evaluate our observations in man.
Owing to the cardiovascular toxicity and market withdrawal of COX-2 inhibitors, such as rofecoxib and valdecoxib, there has been intense interest in finding drugs that might conserve the efficacy of COX-2 selective NSAIDs, while minimizing cardiovascular risk. Microsomal PGES-1 has gained considerable attention because it is an inducible PGE synthase. [1] [2] [3] [4] There are 2 other isoforms of PGE synthase, including mPGES-2 and cytosolic PGES, however, mPGES-1 constitutes the major source of PGE 2 in vivo. 6 The global deletion of mPGES-1 retards atherogenesis, 30 suppresses postinjury neointima hyperplasia, 31 and limits aortic aneurysm formation 32 in mice, without affecting thrombogenesis or blood pressure. 6 Importantly, the deletion of mPGES-1 results in the rediversion of accumulated PGH 2 to augment the formation of PGI 2 , which is in contrast to increased TXA 2 and reduced PGI 2 during the inhibition of COX-2. 33, 34 Therefore, specific mPGES-1 inhibitors have been proposed as alternative drugs to COX-2 inhibitors with fewer cardiovascular risks, or as a treatment for attenuating the symptoms of cardiovascular inflammation. However, substrate rediversion may vary with cell type, and the relative dominance of cell types may differ during the evolution of complex diseases. This is exemplified by the aggravated response to injury in endothelial or VSMC target deletion but reduced restenosis in myeloid target deletion of mPGES-1 mice. 35 This is also the case for mPGES-1-derived PGE 2 in VSMCs, which buffers angiotensin II-induced vasoconstriction by inhibiting the production of NADPH oxidase-dependent reactive oxygen species. 32 Our study further extends the complexity of mPGES-1 by showing that its inhibition in VSMCs stimulated mineralization. Special caution needs to be taken in the development of mPGES-1 targeting drugs for clinical application, especially for certain patients with a history of cardiovascular disease or CRF with disturbed calcium/phosphate metabolism. PGE 2 , a metabolite of arachidonic acid produced by COX and PGES, is a recognized mediator of pain and inflammation. Substantial evidence has shown that PGE 2 is involved in atherosclerosis, 36 hypertension, 37 aneurysms, 38 and restenosis. 39 However, the role of PGE 2 in vascular calcification remains elusive. During the past decade, our understanding of the pathogenesis of vascular calcification has been advanced through the recognition that its process shares many similarities to that of skeletal mineralization. 8,9 PGE 2 is an essential regulator of both bone desorption and formation. 11 PGE 2 inhibited in vitro mineral deposition through modulating Runt-related transcription factor 2 (Runx2) and its functional antagonist TWIST1 in human periodontal ligament cells. 40 In osteoblasts, PGE 2 increased C/EBP expression and enhanced transactivation by Runx2. 41 These paradoxical roles of PGE 2 in osteogenesis or calcification may be because of the distinct cell types and respective receptors. Further studies need to be explored specifically on VSMCs. PGE 2 -specific receptors including EP1, EP2, EP3, and EP4 were widely expressed on VSMCs. 22 Here, we explored that only EP2 and EP4 were upregulated by high Pi in VSMCs ( Figure 7A and 7B). Furthermore, EP4 antagonist and EP4 knockdown amplified high-Pi-induced VSMC calcification, whereas EP2 inhibition displayed no effects ( mice. 42, 43 Moreover, the EP4 pathways was also discovered to mediate the PGE 2 -inhibited mineralization in mature cementoblasts. 44 Thus, combined with previous findings, our data indicated EP4 might be the major receptor mediated the protective role of PGE 2 on VSMCs calcification. Recently, Wirrig et al 45 reported that COX-2 inhibition reduced aortic valve calcification evidenced by the decreased osteogenic gene expression and calcium deposition. Although they reported COX-2 was similarly upregulated in calcific aortic valve disease, they demonstrated that COX-2 inhibition reduced the aortic valve calcification, which seemed contradictory to our findings in VSMCs. One of the major reason is aortic valvular interstitial cells calcification differ with VSMCs calcification. 46, 47 However, PGE 2 exhibits its different effect via its 4 receptors individually. We found that EP4 might mainly mediate the protective effect of PGE 2 on VSMC calcification (Figure 7) . It is still not known which EP subtypes are distributed in valvular interstitial cells. Thus, to further confirm the types of PGE 2 receptors expressed by valvular interstitial cells might be favorable to explain the opposite results between Wirrig et al's 45 and ours. VSMCs osteochondrogenic transdifferentiation was involved in VSMCs calcification. Osteogenic master regulator Runx2 was reported to inhibit myocardin transcription and, in turn, decrease SMC differentiation markers, 48 indicating the crosstalk between VSMCs dedifferentiation and osteogenesis. Thus, the SMC differentiation markers partially restored by PGE 2 ( Figure 3D ) was possibly involved in PGE 2 -suppressed VSMC calcification. However, vascular calcification involves complex underlying mechanisms, including matrix vesicle, loss of inhibitor, ALP activation, Pit-1 transportation, autophage, senescence, and apoptosis, etc. On the basis of our results, PGE 2 not only restored the differentiation marker but also inhibited the expression of osteogenic gene, the ALP activity, and VSMCs apoptosis ( Figure 3C-3E ), indicating PGE 2 might regulate multiple aspects of VSMC function to inhibit VSMC calcification.
In summary, our data reveal a regulatory effect of the COX-2-mPGES-1-PGE 2 axis on VSMC calcification. The inhibition of COX-2 or mPGES-1 may increase the risk of vascular calcification and, therefore, lead to predisposition to adverse cardiovascular events. Special caution is needed for selective mPGES-1 inhibitors as an alternative strategy to selective COX-2 inhibitors in certain indications, such as patients with chronic renal failure.
